Drug Profile
Onartuzumab - Genentech
Alternative Names: 5D5; anti-c-Met monoclonal antibody - Genentech; hOA-5D5.v2; MetMAb; OA-5D5; PRO-143966; RG-3638; RO-5490258Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Genentech
- Developer Chugai Pharmaceutical; Genentech
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Colorectal cancer; Gastric cancer; Glioblastoma; Liver cancer; Non-small cell lung cancer; Solid tumours; Triple negative breast cancer
Most Recent Events
- 19 Jul 2018 Roche completes a phase III extension trial for Solid tumours in Latvia, Spain, France, Russia, Italy, Japan, Serbia and South Africa (NCT02488330)
- 01 Mar 2016 Genentech completes a phase II trial in Breast cancer (First-line therapy, second-line therapy or greater, metastatic disease, combination therapy) in USA, Belgium, France, Germany, Spain and United Kingdom (IV) (NCT01186991)
- 28 Jan 2016 Roche completes a phase III MetLung trial in Non-small cell lung cancer (Second-line therapy or greater, Combination therapy, Late stage disease, Metastatic) in Argentina, Australia, Belgium, Brazil, Canada, Chile, Croatia, France, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, South Korea, Netherlands, Peru, Poland, Russia, Serbia, South Africa, Spain, Taiwan, Ukraine, United Kingdom and USA (IV,Infusion) (NCT01456325) (EudraCT2011-002224-40)